Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index
- 2 March 2006
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 133 (1), 43-49
- https://doi.org/10.1111/j.1365-2141.2006.05970.x
Abstract
The International Prognostic Index (IPI) is the most commonly used prognostic model for mantle cell lymphoma (MCL). However, the prognostic value of the IPI is limited. The recently published Follicular Lymphoma International Prognostic Index (FLIPI) is built on variables, which are pertinent to MCL. This study was conducted to evaluate the prognostic value of FLIPI in a population-based series of 93 patients with MCL diagnosed in a 7-year period. End points of the study were response to therapy, overall survival, and disease-free survival (DFS) according to the IPI and FLIPI. Applied to the whole series, the FLIPI identified three risk groups with markedly different outcome with 5-year overall survival rates of 65%, 42%, and 8% respectively. Notably, the high-risk group comprised 53% of patients. In contrast, the IPI only allocated 16% of cases to the high-risk group and had a lower overall predictive capacity. When both the FLIPI and IPI were included in a multivariate analysis, only the FLIPI was related to survival. Multivariate analysis of DFS also identified the FLIPI, and not the IPI, as independently significant. Thus, in the present study, the FLIPI was superior as a prognostic model compared with the IPI and can therefore be recommended as a clinical prognostic index for MCL.Keywords
This publication has 27 references indexed in Scilit:
- Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcomeBlood, 2005
- Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL NetworkPublished by American Society of Hematology ,2005
- Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)Journal of Clinical Oncology, 2005
- Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell LymphomaJournal of Clinical Oncology, 2005
- Follicular Lymphoma International Prognostic IndexBlood, 2004
- Mantle cell lymphoma: established therapeutic options and future directionsAnnals of Hematology, 2004
- Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remissionCancer, 2003
- A Danish population-based analysis of 105 mantle cell lymphoma patientsEuropean Journal Of Cancer, 2002
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Mantle Cell Lymphoma A Proposal for Unification of Morphologic, Immunologic, and Molecular DataThe American Journal of Surgical Pathology, 1992